India, Dec. 15 -- image credit- freepik

Vyome Holdings, Inc., based both in US and India, has announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (MFW).

VT-1953, a first-in-class immunomodulator for this indication, achieved both its primary and secondary endpoints. With this result, Vyome plans to advance to Phase III pivotal trial, seek US FDA approval, and enter the $1 billion potential addressable market as the only anticipated approved solution for malignant fungating wounds. MFW is a debilitating condition that occurs in 5-14% of advanced cancer patients. It is estimated that there are over 693,000 patients with advanced cancer i...